close

Fundraisings and IPOs

1 2 3 77
Number of results: 1535
Date Company Amount Funding type Investors Therapeutic area Type of Information
2019-03-20 Flagship Pioneering (USA - MA) $824 million financing round undisclosed long-time limited partners, new institutional investors, family offices Financing round
2019-03-11 Snipr Biome (Denmark) $50 million (€43 million, DKK320 million) series A financing round Lundbeckfonden Emerge (Denmark) LSP (Netherlands) North-East Family Office (Denmark) Wellington Partners (Germany) Autoimmune diseases - Cancer - Oncology - Infectious diseases Series A financing round
2019-03-06 Beam Therapeutics (USA - MA) $135 million series B financing round ARCH Venture Partners (USA - IL) F-Prime Capital Partners (USA - MA) Eight Roads Ventures (China - India - USA) Omega Funds (USA - MA) Redmile Group (USA - CA) Cormorant Asset Management (USA - MA) GV (USA - CA) Altitude Life Science Ventures (USA - WA) and additional undisclosed investors Rare diseases - Genetic diseases Series B financing round
2019-02-27 MeiraGTx (USA - NY) $80 million private placement Johnson & Johnson Innovation – JJDC (USA - NJ) Perceptive Advisors (USA - NY) OrbiMed Advisors, (USA - NY) 683 Capital Management (USA - NY) Rare diseases - Genetic diseases Private placement
2019-02-14 Passage Bio (USA - PA) $115.5 million series A financing round OrbiMed Advisors (USA - NY) Frazier Healthcare Partners (USA - WA) Versant Ventures (USA - CA) New Leaf Venture Partners (USA - NY - CA) Vivo Capital (USA - CA) Lilly Asia Ventures (China) Rare diseases - Genetic diseases - CNS diseases Series A financing round
2019-02-12 Neurogene (USA - NY) $68.5 million series A financing round Samsara BioCapital (USA - CA) EcoR1 Capital (USA - CA) Cormorant Asset Management (USA - MA) Redmile Group (USA - CA) undisclosed leading healthcare investment fund. Rare diseases - Genetic diseases - Neurological diseases Series A financing round
2019-01-25 Nordic Nanovector (Norway) NOK 222 million ($ 26 million) private placement Cancer - Oncology Private placement
2019-01-25 Corbus Pharmaceuticals (USA - MA) private placement Inflammatory diseases Private placement
2019-01-24 Wave Life Sciences (USA - MA) $150 million private placement Rare diseases - Genetic diseases Private placement
2019-01-24 Wave Life Sciences (USA - MA) $150 million private placement Rare diseases - Genetic diseases Private placement
2019-01-23 Orion (Finland) € 100 million loan European Investment Bank (EIB) Cancer - Oncology - Neurological diseases - Respiratory diseases Loan
2019-01-23 PTC Therapeutics (USA - NJ) private placement Rare diseases - Genetic diseases Private placement
2019-01-23 Selecta Biosciences (USA - MA) $30 million private placement Private placement
2019-01-22 Alvotech (Iceland) $300 million private placement Autoimmune diseases - Inflammatory diseases - Cancer - Oncology Private placement
2019-01-14 Alnylam Pharmaceuticals (USA - MA) $387.5 million private placement Rare diseases - Genetic diseases Private placement
2019-01-04 Aimmune Therapeutics (USA - CA) $ 170 million loan KKR (USA - NY) Allergic diseases Loan
2019-01-03 Cabaletta Bio (USA - PA) $50 million series B financing round Adage Capital (USA - MA) 5AM Ventures (USA - MA) Deerfield Management Company (USA - NY) Boxer Capital of Tavistock Group  (Bahamas) Redmile Group (USA - CA) Cormorant Capital (USA - IL) Autoimmune diseases Series B financing round
2018-12-21 Nabriva Therapeutics (Ireland) $75 million loan Hercules Capital (USA - CA) Infectious diseases Loan
2018-12-20 Geneuro (Switzerland) €7.5 million credit line GNEH (France) Neurodegenerative diseases Loan
2018-12-19 Altheia Science (Italy) $19.3 million (€17 million) series A financing round Fin Posillipo SpA, holding company of Petrone Group (Italy) the Rovati family’s Fidim (Italy) Rottapharm Biotech (Italy) undisclosed seasoned private players with successful track record in the biotech sector Autoimmune diseases - Cancer - Oncology Series A financing round